Tier 2 — strong

The effects of quercetin supplementation on metabolic and hormonal parameters as well as plasma concentration and gene expression of resistin in overweight or obese women with polycystic ovary syndrome

Masoud Khorshidi, Ashraf Moini, Elham Alipoor, Neda Rezvan, Sattar Gorgani-Firuzjaee, Mehdi Yaseri, Mohammad Javad Hosseinzadeh-Attar
Phytotherapy research : PTR 2018 32(11):2282-2289

Bibliography

PubMed
PMID 30062709
DOI
10.1002/ptr.6166
Funding
Indexed grant support: 33057 — Tehran University of Medical Sciences and Health Services. The indexed list may not contain the complete funding declaration.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled PCOS trial
ModelHuman intervention research
Sample78 overweight or obese women with PCOS
InterventionQuercetin 1,000 mg/day versus placebo
Duration12 weeks
EndpointsGlucose and insulin measures

What the study showed, in plain terms

Published in 2018, this source examined hormones and reproductive health. Design: Randomized double-blind placebo-controlled PCOS trial. Sample/model: 78 overweight or obese women with PCOS. The exposure or intervention was Quercetin 1,000 mg/day versus placebo. Follow-up or treatment period: 12 weeks.

Resistin, testosterone and LH measures decreased relative to placebo. Glucose, insulin and HOMA-IR changes were not significant between groups.

Selected hormonal and molecular outcomes. Within-group glycemic changes should not be presented as a placebo-controlled diabetes benefit.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin Benefits: What Human Studies Actually Show. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Resistin, testosterone and LH measures decreased relative to placebo.
  • Glucose, insulin and HOMA-IR changes were not significant between groups.
  • The recorded outcome domains were Glucose and insulin measures.
  • The result applies to the tested exposure: Quercetin 1,000 mg/day versus placebo; 12 weeks.

What this study can and cannot tell us

  • Selected hormonal and molecular outcomes. Within-group glycemic changes should not be presented as a placebo-controlled diabetes benefit.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Quercetin and polycystic ovary syndrome; inflammation, hormonal parameters and pregnancy outcome: A randomized clinical trial
Sima Vaez et al. · American journal of reproductive immunology (New York, N.Y. : 1989) · 2023
Tier 2
Oral Quercetin Supplementation Enhances Adiponectin Receptor Transcript Expression in Polycystic Ovary Syndrome Patients: A Randomized Placebo-Controlled Double-Blind Clinical Trial
Neda Rezvan et al. · Cell journal · 2018
Tier 2
Effects of Quercetin on Adiponectin-Mediated Insulin Sensitivity in Polycystic Ovary Syndrome: A Randomized Placebo-Controlled Double-Blind Clinical Trial
N Rezvan et al. · Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2017

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology